20）Missailidis C, Hällqvist J, Qureshi AR, Barany P, Heimbürger O, Lindholm B, et al. Serum trimethylamine-N-oxide is strongly related to renal function and predicts outcome in chronic kidney disease. PLoS One 2016; 11: e0141738.21）Stubbs JR, House JA, Ocque AJ, Zhang S, Johnson C, Kimber C, et al. Serum trimethylamine-N-oxide is elevated in CKD and correlates with coronary atherosclerosis burden. J Am Soc Nephrol 2016; 27: 305-13.22）Li DY, Wang Z, Jia X, Yan D, Shih DM, Hazen SL, et al. Loop diuretics inhibit renal excretion of trimethylamine N-oxide. JACC Basic Transl Sci 2021; 6: 103-15.23）Li DY, Li XS, Chaikijurajai T, Li L, Wang Z, Hazen SL, et al. Relation of statin use to gut microbial trimethylamine N-oxide and cardiovascular risk. Am J Cardiol 2022; 178: 26-34.24）Zhernakova A, Kurilshikov A, Bonder MJ, Tigchelaar EF, Schirmer M, Vatanen T, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 2016; 352: 565-9.25）Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655-63. 26）Hasegawa T, Asakura M, Eguchi K, Asanuma H, Ohara T, Kanzaki H, et al. Plasma B-type natriuretic peptide is a useful tool for assessing coronary heart disease risk in a Japanese general population. Hypertens Res 2015; 38: 74-9.27）Salzano A, Israr MZ, Yazaki Y, Heaney LM, Kanagala P, Singh A, et al. Combined use of trimethylamine N-oxide with BNP for risk stratification in heart failure with preserved ejection fraction: findings from the DIAMONDHFpEF study. Eur J Prev Cardiol 2020; 27: 2159-62.171
元のページ ../index.html#189